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Purpose or Objective: Patients suffering from high-grade 
gliomas currently have a median survival time of 14 months 
despite treatment. Our purpose was to investigate whether 
MR perfusion and relative Cerebral Blood Volume (rCBV) maps 
could predict tumor recurrence areas and improve treatment 
planning. 
 
Material and Methods: This retrospective study included 19 
patients suffering from high grade gliomas (3 and 4) who 
received standard radiotherapy [60 Gy, 2 Gy/fraction] and 
Temodal chemotherapy. Subjects underwent pre-treatment 
CT, gadolinium-enhanced T1-weighted, T2 FLAIR acquisitions 
and a DSC-MR scan. rCBV maps were calculated using READE 
View Advantage Workstation (GE) and normalized to the 
normal white matter perfusion value. The PLANET software 
(DOSIsoft) was used to register all MR images to the planning 
CT. A senior radiologist and a senior radiotherapist 
delineated Gross Tumor Volumes (GTV) on anatomical MR 
images. The Planning Target Volumes (PTV) were defined by 
a physicist. Threshold of 1.7 was applied to the rCBV maps to 
define hyper-perfused volumes (Vperf). Follow-up anatomical 
MR images were used to localize recurrence areas (GTV’). 
Correlations between all volumes were analyzed using several 
indexes. I1 is the percentage of Vperf not included in the 
GTV. I2, I3, and I5 are respectively the percentage of GTV’ 
included in Vperf, GTV, and PTV. I4 is the percentage of 
Vperf’ not included in the GTV which was predictive of tumor 
recurrence outside GTV. This index is meaningful only if GTV’ 
and GVT are different.  
 
Results: Indexes obtained for each patient are presented in 
Table 1. For two patients, a threshold of 2 was applied to the 
rCBV maps at the physician request to facilitate the hyper-
perfused area visualization. I1 values are in a range of 4 to 
82% (mean = 43%) and are greater than 20% for almost 90% of 
the patients, indicating that hyper-perfused areas and GTV 
can be different. Hence, rCBV maps provide supplementary 
information. At least 40% of GTV’ is included in Vperf for 16 
patients (I2 index). For 10 patients, GTV’ is not completely 
included in the GTV (I3 < 85%). In all these cases except one, 
the I4 index is greater than 20%, suggesting that a part of 
Vperf is predictive of the recurrence localization (Figure 1). 
I5 being almost always equal to 1 points out that all 
recurrence areas received the same dose as the GTV.  
 
 
 
 
Conclusion: Our results suggest that rCBV perfusion maps can 
be predictive of recurrence localization. I1, I2 and I4 values 
are however entirely dependent on the threshold applied to 
rCBV maps and their evolution while the threshold increases 
will be studied. As recurrence areas are always included in 
the PTV, an improvement of treatment planning would 
consist in boosting hyper-perfused area rather than changing 
the GTV delineation. An in-depth analysis of the pre-
treatment rCBV values observed in recurrence areas will be 
conducted to better describe potential boost areas.  
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